The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Fingolimod for Multiple Sclerosis
Abstract
A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Self-citation(2006) · Elsevier eBooks · doi:10.1016/b978-0-443-07271-0.x5001-0 · Cited by 769
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22128 · Cited by 433
Pham, T. H. M., Okada, T., Matloubian, M., Lo, C. G., & Cyster, J. G. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.017 · Cited by 427
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States
Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O. (2006) · Neurology · doi:10.1212/01.wnl.0000218309.01322.5c · Cited by 286
Trends in survival and cause of death in Danish patients with multiple sclerosis
Bronnum-Hansen, H. (2004) · Brain · doi:10.1093/brain/awh104 · Cited by 282
Edsall, L. C., Pirianov, G. G., & Spiegel, S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-06952.1997 · Cited by 275
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Miron, V. E., Ludwin, S. K., Darlington, P. J., Jarjour, A. A., Soliven, B., Kennedy, T. E., & Antel, J. P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091234 · Cited by 267
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Self-citationFTY720 modulates human oligodendrocyte progenitor process extension and survival
Miron, V. E., Jung, C. G., Kim, H. J., Kennedy, T. E., Soliven, B., & Antel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21227 · Cited by 255
Natural history of secondary-progressive multiple sclerosis
Tremlett, H., Zhao, Y., & Devonshire, V. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084264 · Cited by 217
Sphingosine‐1‐phosphate induces proliferation and morphological changes of neural progenitor cells
Harada, J., Foley, M., Moskowitz, M. A., & Waeber, C. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02219.x · Cited by 203
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
Mehling, M., Lindberg, R., Raulf, F., Kuhle, J., Hess, C., Kappos, L., & Brinkmann, V. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd64 · Cited by 195
Koyrakh, L., Roman, M. I., Brinkmann, V., & Wickman, K. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00754.x · Cited by 166
Life expectancy in patients attending multiple sclerosis clinics
Sadovnick, A. D., Ebers, G. C., Wilson, R. W., & Paty, D. W. (1992) · Neurology · doi:10.1212/wnl.42.5.991 · Cited by 159
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
Comi, G., O'Connor, P., Montalban, X., Antel, J., Radue, E.-W., Karlsson, G., Pohlmann, H., Aradhye, S., Kappos, L., & FTY720D2201 Study Group (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509357065 · Cited by 158
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
Brinkmann, V., Chen, S., Feng, L., Pinschewer, D. D., Nikolova, Z. G., & Hof, R. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02126-6 · Cited by 90
Yamagata, K., Tagami, M., Torii, Y., TAKENAGA, F., Tsumagari, S., Itoh, S., Yamori, Y., & Nara, Y. (2002) · Glia · doi:10.1002/glia.10180 · Cited by 84
Delayed fingolimod-associated asystole
Espinosa, P. S., & Berger, J. R. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511410344 · Cited by 75
Pulmonary and vascular pharmacology of sphingosine 1-phosphate
Brinkmann, V., & Baumruker, T. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.12.004 · Cited by 71
Hu, Y., Lee, X., Ji, B., Guckian, K. M., Apicco, D. J., Pepinsky, R. B., Miller, R. H., & Mi, S. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.06.007 · Cited by 59
Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report
Conzett, K. B., Kolm, I., Jelcic, I., Kamarachev, J., Dummer, R., Braun, R., French, L. E., Linnebank, M., & Hofbauer, G. F. L. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.212 · Cited by 38
Hartung, H., & Aktaş, O. (2009) · Annals of Neurology · doi:10.1002/ana.21880 · Cited by 22
Cited by
Ectopic lymphoid-like structures in infection, cancer and autoimmunity
Pitzalis, C., Jones, G. W., Bombardieri, M., & Jones, S. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3700 · Cited by 698
A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Tu, Y.-F., Chien, C.-S., Yarmishyn, A. A., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., Lai, W.-Y., Yang, D.-M., Chou, S.-J., Yang, Y.-P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072657 · Cited by 686
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy
Proia, R. L., & Hla, T. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76369 · Cited by 528
Animal models of multiple sclerosis: the good, the bad and the bottom line
Ransohoff, R. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3168 · Cited by 379
Hallmarks of Tissue-Resident Lymphocytes
Fan, X., & Rudensky, A. Y. (2016) · Cell · doi:10.1016/j.cell.2016.02.048 · Cited by 354
Metadata
- Authors
- Pelletier, D., & Hafler, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-01-26
- Volume
- 366
- Issue
- 4
- Pages
- 339-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079246512
- Cited by
- 315
- References
- 39
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.